The past few weeks have seen a multitude of developments for **Johnson & Johnson**. The company's stocks have been receiving positive attention from multiple investment firms such as **Talbot Financial LLC**, **NatWest Group plc**, **Osprey Private Wealth LLC**, and **Czech National Bank**, leading to an increase in their purchased shares. However, legal troubles persist with another talc trial ordering Johnson & Johnson to pay $40 million. On a brighter note, the **FDA approved** their **TRUFILL n‑BCA Liquid Embolic System**. Furthermore, **collaborations** were also instituted with the **New York Jets** for community health promotion and J&J CareCommunity for Latin American healthcare support. In addition, the promising progress and optimistic growth outlook led to raised price targets by **Barclays** and **RBC**. Their stock surged by 40% and found support from **Jim Cramer** and **Guggenheim** due to their effective cancer drugs and promising treatments. Other notable events were the Company's request for the first icotrokinra U.S. FDA approval and J&J Impact Ventures' investment in ThinkMD. Lastly, J&J was named to Fortune's **2025 America's Most Innovative Companies** list, highlighting their commitment to innovation.
Johnson Johnson JNJ News Analytics from Mon, 17 Mar 2025 07:00:00 GMT to Sat, 20 Dec 2025 17:11:25 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -5
